A Trial of Long-Acting Injectable Risperidone in the Treatment of Methamphetamine Dependence
Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
Objective of the Project.
-Methamphetamine (MA) use is growing to epidemic proportions and existing treatments for MA
dependence demonstrate sub-optimal efficacy. Research implicates heavy use of MA as at least
a contributing agent to a variety of neuropsychiatric impairments including psychosis, mood
disturbance, anxiety, cognitive deficits, and motor dysfunction. Initial study by this
investigator suggests that agents like risperidone may also be beneficial to MA dependent
individuals by decreasing MA use and improving cognitive function in early abstinence.
Long-acting injectable risperidone may prove more efficacious given its receptor binding
characteristics and potential to increase medication adherence. The study objective is to
determine the safety and efficacy of treating MA dependence and the associated cognitive and
psychiatric symptomatology with long-acting injectable risperidone.
Phase:
Phase 2
Details
Lead Sponsor:
Seattle Institute for Biomedical and Clinical Research